MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To judge multiple intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Most important demo aims ended up To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patients, whilst one of several https://triptolide77553.like-blogs.com/30657538/considerations-to-know-about-qst4